Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 13/20 | 0.42 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685916 | 0.79 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL384991 | 0.79 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL384009 | 0.79 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6672163 | 0.76 | TUBB1 (0.41) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6672156 | 0.76 | TUBB1 (0.41) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1106540 | 0.75 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2058438 | 0.75 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2249926 | 0.74 | CTSK (0.53) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL12634867 | 0.74 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12634863 | 0.74 | CA1 (0.49) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | BCAT1, BCAT2, AADAT | CA1 2632/4885CA2 2882/4885CA7 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.